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ABSTRACT
Introduction: Tuberculosis (TB) is one of the most common infectious diseases
worldwide. One third of the world’s population is infected with TB. Mycobacterium
tuberculosis, the bacterium that causes TB, can infect the body and remain inactive
(latent infection), or the infection can progress and cause the disease. Certain populations
are at a particular risk to develop TB; these groups include persons infected with HIV,
homeless persons, incarcerated individuals, and those who live in areas where TB is
endemic, such as Southeast Asia. The standard treatment regimen to prevent progression
to TB is the nine months of self-administered isoniazid (300 mg) (also known as the 9H
regimen) for the treatment of latent TB infection (LTBI). However, a short regimen of 12
weekly doses of isoniazid (900 mg) plus rifapentine (900 mg), (also known as the 3HP
regimen) has been recently shown to be as effective as the standard regimen with higher
treatment completion rates by the PREVENT TB trial.
The objective of this analysis is to evaluate factors associated with non-completion of
LTBI treatment among homeless participants enrolled in the PREVENT TB trial.
Methods: The study population consisted of 6, 232 participants enrolled in the
PREVENT TB trial after excluding participants enrolled in non-North American sites,
pregnant women, and children. Non-completion of treatment was defined as receipt of:
<11 of 12 doses within 10-16 weeks for 3HP or <240 of 270 doses within 35-52 weeks
for 9H. Missing an early visit was defined as missing ≥1 of the first 3 observed doses in
the 3HP regimen followed by receiving an observed dose during the treatment period; or
missing ≥1 of the first 3 monthly visits in the 9H regimen, followed by a monthly visit at
any time during treatment. Chi-square test, univariate and multivariate logistic regression
analyses were conducted to evaluate demographic, clinical, social, and behavioral factors
associated with non-completion of LTBI treatment in the homeless population by using
SAS® version 9.3 (Cary, North Carolina).
Results: The cohort for analysis included 6,232 participants (3HP = 3,230 and
9H=3,002), of which 505 were homeless (8.1%). Most homeless participants were male
(86.7%), born in the U.S. (87.1%), and African descendants (53.1%). The median age
was 46 compared with 36 in the non-homeless group. Other characteristics associated
with homelessness were unemployment, smoking, alcohol consumption, and use of
concomitant medications. Homeless participants in both treatment regimens were more
likely to be of African descent (p<0.001) and have a BMI classifying them as overweight
(p<0.001). In the multivariate analysis, factors found to be statistically associated with
LTBI treatment non-completion among homeless were: missing an early clinic visit
compared to those who did not miss a clinic visit (OR: 4.57; 95%CI: 2.46, 8.49:
p<0.0001), receiving the 9H regimen (OR: 2.11; 95%CI: 1.40, 3.18; p=0.0003), born in
non-US compared to those who were born in US (OR: 1.96; 95% CI: 1.1, 3.48;
p=0.0220), and history of incarceration (OR: 1.69; 95%CI: 1.11, 2.57: p=0.0148).
Conclusion: Homeless persons present many challenges in treatment for any disease,
particularly one that requires lengthy treatment and follow-up such as tuberculosis, as
well as prophylactic treatment for LTBI. Appropriate interventions to improve
completion of LTBI treatment such as coordination with social and educational programs,
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as well as with homeless shelters, could increase adherence among the homeless
population.

KEYWORDS: homeless, latent tuberculosis, non-completion of treatment

IV

Author’s Statement Page
In presenting this thesis as a partial fulfillment of the requirements for an advanced
degree from Georgia State University, I agree that the Library of the University shall
make it available for inspection and circulation in accordance with its regulations
governing materials of this type. I agree that permission to quote from, to copy from, or
to publish this thesis may be granted by the author or, in his/her absence, by the professor
under whose direction it was written, or in his/her absence, by the Associate Dean,
School of Public Health. Such quoting, copying, or publishing must be solely for
scholarly purposes and will not involve potential financial gain. It is understood that any
copying from or publication of this dissertation which involves potential financial gain
will not be allowed without written permission of the author.

__Deborah Delaguila________
Signature of Author

V

Notice to Borrowers Page

All theses deposited in the Georgia State University Library must be used in accordance
with the stipulations prescribed by the author in the preceding statement.
The author of this thesis is:

Student’s Name: Deborah Delaguila
Street Address: 105 Meadowridge Way
City, State, and Zip Code: Stockbridge, GA, 30281
The Chair of the committee for this thesis is:
Professor’s Name: Dr. Richard Rothenberg
Department: School of Public Health
College: Health and Human Sciences
Georgia State University
P.O. Box 3995
Atlanta, Georgia 30302-3995
Users of this thesis who are not regularly enrolled as students at Georgia State University
are required to attest acceptance of the preceding stipulation by signing below. Libraries
borrowing this thesis for the use of their patrons are required to see that each user records
here the information requested.

Name of User

Address

Date

VI

Type of Use
(Examination only or
Copying)

ACKNOWLEDGEMENTS
I would like to thank the faculty and staff at Georgia State University’s School of Public
Health. I have had a wonderful graduate education experience at Georgia State
University, largely due to your guidance. I extend my gratitude in particular to Dr.
Richard Rothenberg. I feel very privileged to have someone with such expertise and
eminence chair my committee. I also extend my gratitude to Dr. Ruth Moro. Thank you
for your guidance and mentorship on this project. I learned so much from you. I
especially want to thank everyone at the Tuberculosis Trials Consortium (TBTC) at the
Centers for Disease Control and Prevention. In particular, I would like to thank Erin
Sizemore for giving me a chance and taking me on as an intern within the branch. Thank
you Nigel Scott for clarifying my questions about SAS over the course of my project.
You are a wonderful teacher and I admire your intellectualism. Dr. Stefan Goldberg,
thank you for providing valuable input in the final version of my thesis. Dr. Andrey
Borisov, thank you for providing helpful suggestions in the later stages of my thesis.
Thank you to my friends and family for your support. A special thank you to my father,
Gustavo Delaguila, who always emphasized the importance of advancing my education. I
dedicate this thesis to my late mother, Herta. Thank you to Jesus Christ for his many
blessings.

VII

TABLE OF CONTENTS
Acknowledgements………………………………………………………………….….VII
List of Figure/Tables……………………………………………………….………....IX-X
1. Introduction……………………………………………………………………..…11-13
2. Literature Review…………………………………………………………….........13-25
3. Methods and Procedures…………………………………………………………...25-28
4. Results……………………………………………………………......……………28-32
5. Discussion………………………………………………………………………….32-36
6. Conclusion…………………………...………………………...…...…………………36
7. References………………………………………………...………….……………37-40
Figure/ Tables……………………………………………………………………...…41-65

VIII

LIST OF FIGURE/ TABLES
Figure 1. Flow Chart of Participants Evaluated for Factors Associated with Noncompletion of Latent TB Infection Treatment in Homeless Participants Enrolled in
The PREVENT TB Study – North American Sites (from the Tuberculosis Trials
Consortium)…………………………………………………………………………...…41
Table 1. Demographics Characteristics Among Homeless and Non-Homeless
Participants in the United States and Canadian Sites in the PREVENT TB Trial…….....42
Table 2. Demographic Characteristics of Homeless Participants in the PREVENT TB
Trial, Stratified by Treatment Regimen……………………………………………….....45
Table 3. LTBI Treatment Completion, Stratified by Homelessness and by Treatment
Regimen……………….……………………………………………………………...….47
Table 4A. Reasons for not Completing LTBI Treatment, Stratified by Homelessness
Status Among Participants Assigned to the 9H Regimen…………………..……………48
Table 4B. Reasons for not Completing Treatment, Stratified by Homelessness Status
Among Participants Assigned to the 3HP Regimen…………………………………..…48
Table 4C. Classification of “Other” Reason for Non-completion of Treatment in the 9H
Regimen, Stratified by Homeless Status ……………………………………..……….…49

Table 4D. Classification of “Other” Reason for Non-completion of Treatment in the 3HP
Regimen, Stratified by Homeless Status…………………………………………………49

Table 5. Factors Associated with Non-completion of LTBI Treatment in Homeless
Participants – Univariate Analysis……………………………………………….………50

Table 6. Factors Associated with Non-completion of LTBI Treatment Among Homeless
Participants – Multivariate Analysis…………………………………………………..…52

Table 7. Homeless Participants Stratified by Regimen and Site…………..……….……53

Table 8. Clusters of Participants Enrolled in the PREVENT TB Trial, Stratified by
Homelessness Status………………………………………………………..…………...54
IX

Table 9. Clusters of Homeless Participants Enrolled in the PREVENT TB Trial Stratified
by Treatment Regimen…………………………………………………………….….….55
Table S1. Demographic Characteristics Among First Participants Enrolled in a
Cluster, Stratified by Homeless Status…………………………………………..……….57

Table S2. Demographic Characteristics of the First Homeless Participants Enrolled in a
Cluster, Stratified by Treatment Regimen………………………………………….……60

Table S3. Factors Associated with Non-completion of LTBI Treatment Among the First
Homeless Participant Enrolled in a Cluster – Univariate Analysis……………….……..63

Table S4. Factors Associated with LTBI Non-completion of Treatment Among the First
Participant Enrolled in a Cluster - Multivariate Analysis ……………………….………65

x

1. INTRODUCTION
Tuberculosis (TB) is one of the most common infectious diseases worldwide.
Although the rate of TB in the United States (U.S.) has declined significantly in recent
years (2.96 cases per 100,000 persons) with a total of 9,421 cases in 2014, compared to
10.4 cases/ 100, 000 26,673 cases, at the peak of the historical resurgence in 1992 (CDC,
http://www.cdc.gov/tb/statistics/reports/2014/pdfs/tb-surveillance-2014-report.pdf). TB
still remains a public health problem in the U.S. Efforts to control tuberculosis are
challenged by a variety of factors. TB therefore persists as a public health concern,
though on a smaller scale than that of the rest of the world. Its looming global presence
highlights the importance of controlling it in the U.S. (CDC,
http://www.cdc.gov/tb/topic/globaltb/default.htm). TB is caused by a bacterium,
Mycobacterium tuberculosis, that is spread from person to person via droplet aerosols.
TB mainly affects the lungs, but it can present in other parts of the body, such as the
kidneys and brain (CDC,
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). Despite the
steady decline of TB in the U.S., there is a disproportionate burden of TB among racial
and ethnic minorities (CDC, http://www.cdc.gov/tb/topic/globaltb/default.htm). Due to
airborne spread, persons in close contact with persons with TB are thus at a high risk of
acquiring TB. Once M. tuberculosis enters a person’s body, it has the capacity to cause
TB disease, unless the person’s immune system suppresses the infection. There is an
interplay of various factors that affects whether TB will develop into disease or it will
remain latent. Persons with conditions that affect the immune system are at particular risk
of developing TB when coming into contact with a known TB case. Such conditions
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include: substance abuse, diabetes mellitus, silicosis, cancer of the head or neck,
leukemia or Hodgkin’s disease, severe kidney disease, low body weight, treatment for
rheumatoid arthritis or Crohn’s disease, and steroid or immunosuppressive treatments for
organ transplants (CDC,
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). TB is a
particular risk in HIV positive persons. HIV suppresses the immune system and increases
the likelihood that latent TB will progress to active TB (CDC,
http://www.cdc.gov/tb/publications/factseries/tbandhiv_eng.htm). These conditions, some
more than others, are represented well in the U.S. The steady decline in TB in the U.S.
should not diminish our efforts in eliminating TB.
TB is unique among the spectrum of infectious diseases. It is contagious in
droplet form and preys upon underserved people as well as those who reside in crowded
living conditions. Its treatment is lengthy. TB is a worldwide burden in countries that are
underdeveloped. While treatment is available for TB, many challenges inhibit people
from seeking and complying with treatment. Worldwide, many people with active TB
disease do not have access to health care and reside in suboptimal living conditions
fraught with poor ventilation and crowding.
Standard treatment regimens for active TB disease are lengthy (CDC,
http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease). Six to nine
months of antibiotics for treatment would be challenging for anyone to take, especially
for someone who has adverse social factors such as homelessness and unemployment.
Treatment regimens for latent TB are equally lengthy and demand compliance and
consistency (CDC, http://www.cdc.gov/tb/topic/treatment/ltbi.htm). There is a risk for
12

dangerous health outcomes should patients decide to withdraw from treatment or not take
the medicines appropriately. Perhaps these difficulties in treatment compliance have kept
TB at the forefront of public health.
Homeless people face many challenges both socially and medically. Their
disadvantaged status does not bode well for their general well-being, especially their
health. They live in crowded conditions, have limited access to medical care, and are
underserved, which make them ideal repositories for the TB bacillus. TB is not a disease
that is managed easily and it is especially difficult for homeless persons to receive health
care. Requiring homeless persons to complete treatment for LTBI and active TB is
challenging.
2. LITERATURE REVIEW
Data and Statistics
One third of the world’s population is infected with M. tuberculosis. In its
asymptomatic form, it is called latent TB infection (LTBI). While alarming, this statistic
does not suggest that one third of the world’s population has active TB disease. One third
of the population has been infected with the causative bacterium of TB but has not
developed the disease and it will not transmit to others. The WHO also estimated that
there were over 9 million new cases worldwide of TB in 2014 (WHO
http://www.who.int/gho/tb/en/, 2015). The burden of TB is mostly in developing
countries- 95% of all cases and deaths occur in developing countries.
TB was accountable for the deaths of 1.1 million persons non-infected with
Human Immunodeficiency Virus (HIV) and 0.36 million persons infected with HIV
13

(WHO, http://www.who.int/gho/tb/en/, 2015). HIV is a particular risk factor for the
development of TB. In fact, persons infected with HIV have a 26 to 28 fold risk of
developing TB. In addition, TB is the leading cause of death among persons infected with
HIV, causing 25 percent of all HIV-associated deaths. Not only is infection of M.
tuberculosis a threat to develop the disease, but death from TB is a threat to persons
infected with HIV due to their immunocompromised status (WHO,
http://www.who.int/hiv/topics/tb/tbhiv_facts_2015/en/).
The Worldwide Geography of TB
The distribution of TB varies by region. The most recent statistics demonstrate
that the regions with the greatest number of new TB cases for 2013 were in Southeast
Asia and Western Pacific regions (WHO,
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). Yet
Africa reported the greatest number of new cases per population, with 280 cases per 100,
000 for 2013 (WHO,
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1).
Although rates of TB still remain high in parts of the world where TB is endemic, such as
Southeast Asia and the Western Pacific, part of the recent decline in TB rates can be
attributed to the six point elimination strategy to reduce TB. The WHO has embraced the
END TB strategy, which employs prevention and research in an effort to engage partners
from multiple sectors of the community with the common goal of eliminating TB (WHO,
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). The
goal of the END TB Strategy is to reduce deaths associated with TB as well as reduce TB
incidence. Parts of the END TB Strategy include screening high-risk groups, treatment of
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all patients with TB, management of TB in tandem with management of comorbidities,
effective infection control, social support of those with TB in order to prevent
discrimination from diagnosis, and integrating findings from the most recent research
about TB as well as continuing to study TB treatments in order to ascertain the best
treatment strategies for particular groups.
The Burden of TB in the United States
In the U.S., the majority of TB cases occur in persons who are foreign-born. In 2014,
according to the CDC, 66% of the TB cases in the U.S. occurred among foreign-born persons.
Thus, TB in the U.S. reflects in some ways the statistics of global TB. Therefore, most of the
CDC’s TB control activities focused in high-burden countries can help to reduce the incidence of
TB in the US (CDC http://www.cdc.gov/tb/topic/globaltb/default.htm). In this effort, the CDC
provides technical assistance and research projects to improve TB control in several countries of
the world with a high TB burden such as Botswana, Cambodia, China, Guyana, Ethiopia, Haiti,
India, Kenya, Lesotho, Mexico, Peru, Philippines, Russia, South Africa, Thailand, and Vietnam.
In the early 1900s, one of every seven people died of TB in the U.S. and Europe (CDC
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). After the discovery
of antibiotics such as streptomycin around the 1940s, the incidence of new TB cases started to
slowly decrease in the US (CDC
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). This led to a decrease
in TB control activities around the nation. An important factor that contributed to an upswing of
TB cases in the US was the emerging HIV epidemic in the early 1980s (Core Curriculum on TB:
What the Clinician Should Know, 2011 ) and an influx of immigrants to the U.S. from countries
where TB is endemic, such as Southeast Asia. This increase in TB cases supported the argument
to increase funding for TB control and to focus on improving TB control activities. Fortunately,
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with special attention, there has been a steady decline in TB in the U.S. since then and the
incidence rate has gotten to the lowest in the history of the US. The CDC reports that 9, 421 cases
of TB were reported in the US in 2014 (CDC http://www.cdc.gov/tb/statistics/default.htm). A
lesson was presented, that in order to keep the disease contained, constant efforts are needed by
TB programs and institutions. As programs contract, with tightening budgets, it remains to be
seen whether the lesson was learned.

Children and TB
Pediatric TB is a public health problem of special interest since the finding of a
new case indicates recent transmission, in most cases from a contagious adult with TB.
2013 estimates from the WHO indicate that children contributed more than 500,000 new
cases and that 74, 000 children die from TB annually (WHO,
http://www.who.int/tb/challenges/childtb_factsheet.pdf?ua=1) . Also in 2013, a total of
485 cases (5% of the total) were reported among children younger than 15 years of age in
the U.S., while the proportion of pediatric TB could be as high as 20 % of the total cases
of TB in high burden countries (CDC
http://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm ). TB in children
younger than 5 years of age is of clinical importance since life-threatening and the most
severe forms of TB disease, such as disseminated TB and TB meningitis, develop at this
age group.
Once infected with the Mycobacterium tuberculosis, children are more likely to
develop active TB disease than adults. This process also tends to occur more quickly in
children (CDC http://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm ).
Symptoms of TB in children are similar to the symptoms of TB in adults.
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The CDC has identified TB in children as a “hidden epidemic” in the world.
Many underdeveloped countries do not have resources to adequately diagnose TB and
thus the reporting of cases may be underestimated. Children also struggle to cough up the
sputum that is needed to test for TB, making a TB diagnosis more difficult. The WHO
estimates that 10 million children were orphaned by parental deaths from TB in 2010.
Children are most often infected with TB by close contacts, such as family members
(CDC http://www.cdc.gov/tb/topic/populations/tbinchildren/global.htm).
Pathogenesis of TB
TB is caused by the M. tuberculosis. It is spread from person to person via
droplets from the person infected with M. tuberculosis. TB often affects the lungs, but
can affect other parts of the body such as the bones, kidney and brain (CDC,
http://www.cdc.gov/tb/topic/basics/default.htm, 2015). TB is highly infectious in nature
because it is spread through airborne droplets from an infected person (Tuberculosis:
Pathogenesis, Protection, and Control, 1994). In fact, infectious particles with M.
tuberculosis are emitted when an infected person speaks, coughs, or sneezes. There are
variables in transmission of TB, including the “amount and concentration of bacilli
present in the source case, the duration of exposure, and the aerodynamics of the inhaled
particles” (Tuberculosis: Pathogenesis, Protection, and Control, 1994). Cough is a
common symptom of pulmonary TB (Tuberculosis: Pathogenesis, Protection, and
Control, 1994). The cough may begin as nonproductive but progress to a cough that is
productive in sputum. The signs and symptoms of TB vary with the site involved, but in
general the systemic signs of infection include fatigue, weight loss, and low grade fever.
Diagnostic criteria for TB include sputum culture to confirm the presence of M.
17

tuberculosis as well as chest x-ray. Induced sputum, as well as bronchoscopy, are
methods of obtaining a specimen if the patient is unable to produce sputum.
Latent TB
In addition to active TB disease, latent TB is also a concern. Initial acquisition of
the M. tuberculosis bacterium does not develop into active TB disease in most persons
(Jasmer, 2002). A person’s immunity often keeps the infection latent. However, latent
TB can easily progress to active TB if left untreated. It is therefore important that latent
TB infection be treated with the same attention as active TB. More than 80 percent of
active TB cases in the U.S. stem from latent TB (Hartman-Adams, 2014). Co-infections
that depress the immune system, or aging, may contribute to a flare up of the latent
bacillus and develop into TB (Tuberculosis: Pathogenesis, Protection, and Control,
1994). These first two years after infection pose the greatest threat to the development of
active TB (Geiter, 2000). Failing to seek treatment for latent TB infection poses a five
percent risk of developing active TB in the first two years after infection. There is a ten
percent risk of developing active TB disease in individuals with normal immune systems
who carry latent TB infection (Core Curriculum on Tuberculosis: What the Clinician
Should Know, 2011). Treatment of latent TB is one of the strategies employed to
eliminate TB in the U.S. Identifying and treating persons with latent TB may perhaps be
the best method to reduce TB rates in high risk groups such as homeless persons
(Bamrah, 2013). Despite the importance of identifying cases of latent TB, they are not as
carefully measured as active TB cases (McAdam, 2009). Latent TB does not have the
attendant symptoms that active TB does, and is often asymptomatic, thus causing some
patients to prevent seeking or complying with treatment (Horsburgh Jr., 2004). Even
18

when treatment of latent TB is prescribed, treatment completion rates are low (Horsburgh
Jr., 2004). Lengthy regimens to treat LTBI as well as drug side effects are the main
reasons for low treatment completion rates.
Groups at Risk for TB
Certain populations are especially at risk for TB. These groups include drug
users, homeless persons, and HIV positive individuals, among others. TB is a particular
threat among those populations who reside in crowded conditions (CDC, 2015). The
WHO also lists the following groups of people as risk groups for TB: being an illicit drug
user, being an immigrant from a country where TB is endemic, and those who have had
recent contact with a person who has TB. These groups of people are often co-infected
with HIV and latent TB infection (Lobato, 2005). HIV may depress the immune system
and can cause that LTBI infection develop into active TB disease. Even if persons within
these groups are identified, treatment compliance is problematic. Incarcerated persons are
also a vulnerable population at risk for TB. The CDC cites several reasons that place
inmates at risk of contracting TB: living conditions at correctional facilities such as
overcrowding, close living quarters and inadequate ventilation, difficulty with follow up
once a TB patient is released from prison, or when a TB patient is newly incarcerated,
language barriers and barriers to health care, and HIV co-infection with TB. In the study
by Lobato et al., a study of treatment completion and acceptability was conducted that
enrolled jail inmates as well as homeless persons in five jails throughout the United
States. In the recruitment phase of the study, nineteen percent declined treatment for
LTBI. Overall, 561 1,211 participants completed treatment, resulting in a completion rate
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of 46.3%. This study found most participants were male, black or Hispanic, were
intravenous drug users, and were unemployed.
HIV and TB Co-Infection
HIV is a known risk factor for TB but little research has been conducted to
elucidate the role that TB plays in the course of HIV. One African study sought to delve
into this relationship. Eighty persons with HIV and in definite stages of TB (latent, no
TB, and active TB) were included in this study. Persons with HIV had not yet begun
antiretroviral therapy. Biomarker analysis as well as flow cytometric analysis were
performed on the plasma of the subjects. Despite the small sample size, this study
supported the idea that not only active TB patients had systemic inflammation but also
that patients with latent TB infection had elevated T-cell activation (Sullivan, 2015).
Therefore, latent TB poses a danger to persons with HIV by possibly accelerating the
progression to AIDS and, therefore, earlier mortality.
The presentation of TB in persons with HIV may be unique and not readily
identifiable (Pimpin, 2011). TB and HIV co-infection also presents the challenge of
disease management of both. Drug interactions, an increase in the number of pills to be
taken, as well as potentially exacerbated medication side effects/ toxicity are some of the
challenges faced by patients co-infected with HIV and TB. A systematic review found
that risk factors for HIV-TB co-infection were “homelessness, imprisonment, alcohol
abuse, sharing syringes, and close contact with a TB case” (Pimpin, 2011). This study
underlined the fact that risk factors for HIV and TB overlap. It also revealed that many
studies did not routinely screen TB patients for HIV. More concerted efforts need to be
undertaken to test TB patients for HIV. However, persons with TB may decline to be
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tested for HIV, for various reasons. The CDC recommends that all patient with TB,
including latent TB, be screened for HIV.
Treatment for TB
Treatment for active TB is mandatory to prevent transmission to the general
public. Standard treatment regimens are lengthy and do not encourage compliance.
Current standard treatment regimens for TB consist of a variety of drugs to be taken for 6
to 9 months (CDC,
http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease). Four drugs are
considered to be the main lines of defense: isoniazid, rifampin, pyrazinamide, and
ethambutol. These months of treatment are split up into the initiation phase and followed
by the continuation phase (Blumberg, 2005). The continuation phase is either 4 or 7
months (CDC, http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease).
There are baseline as well as periodic clinic visits throughout the course of treatment to
monitor response to therapy and to discover and address any adverse events or untoward
symptoms that develop from treatment. Many treatment medications have side effects
and adverse effects that can be dangerous or can inhibit treatment compliance. Such
adverse effects include hepatotoxicity and thrombocytopenia (Jasmer, 2002). Any
interruption or premature discontinuation of therapy may lead to drug resistant TB and
continuation of TB disease in the individual (CDC,
http://www.cdc.gov/tb/topic/drtb/default.htm, 2015). Directly observed therapy (DOT)
has been an important part of treatment to encourage compliance. DOT means taking the
prescribed medications in the presence of a healthcare provider. Implied in directly
observed therapy is that participants understand the importance of complying with
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treatment and showing up at assigned appointment times. Quarantines may be
implemented for patients with active TB who do not wish to begin treatment. Quarantines
are important to protect the health of the general public, as TB can be easily transmitted.
Multi-Drug Resistant Tuberculosis (MDRTB)
MDRTB is TB that is resistant at least to isoniazid and rifampicin, the two drugs
that are the main line of defense against TB. In 2013, 480,000 people worldwide
developed MDRTB (WHO,
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1).
Inappropriate use of anti-TB drugs and treatment interruption can lead to MDRTB.
MDRTB also can be acquired by airborne transmission from persons with MDRTB.
Once TB has progressed to MDRTB, treatment options include additional anti-TB agents
that may be less effective, may not be readily available, are expensive, and can cause
multiple side effects (CDC, http://www.cdc.gov/tb/topic/drtb/default.htm).
PREVENT TB Trial
The PREVENT TB Trial, of the TB Trials Consortium (TBTC) was a
randomized, open label phase 3 clinical trial that tested a shorter treatment regimen for
latent TB infection (LTBI). This trial was conducted in the U.S., Canada, Brazil, and
Spain and evaluated the standard treatment regimen of daily self-administered isoniazid
(300 mg) for nine months (9H) against the shorter treatment regimen of once –weekly
rifapentine (900 mg) and isoniazid (900 mg) for three months given under DOT (3HP).
After all participants in the study were followed over 33 months, the trial showed that the
short regimen was as effective as the standard regimen to treat LTBI (Sterling, 2011).
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Treatment compliance was better in the shorter treatment regimen and thus supported the
efficacy of a shorter treatment regimen for latent TB infection. Yet participants assigned
to the combination therapy regimen were “more likely to have permanent drug
discontinuation owing to an adverse event’ (Sterling, 2011). Some of these events were
later identified as Systemic Drug Reactions, most of which presented as a flu-like
syndrome. Groups at increased risk to develop this type of reaction were of white race,
female sex, increased age, and lower BMI. Most of the reactions were mild and resolved
within 24 hours (Sterling et al., 2015). One of the main adverse events in the standard
treatment regimen group was hepatotoxicity.
Homeless Persons and Tuberculosis
Homeless people have various factors that cause instability in their lives and, thus,
prevent treatment compliance. Homeless people possess characteristics that, individually,
place them at a higher risk of TB infection. Two main groups of persons encouraged to
be tested for latent TB infection include persons recently in contact with known TB cases
and those at risk of progression to active TB disease due to factors such as depressed
immune systems and being a native from a country where TB is burdensome (Blumberg,
2005). Homeless persons fall into both of these categories. Homeless persons lead
itinerant lives, often moving in and out of homeless shelters where they are in close
proximity to people with marginal health, at best. Homeless persons often have
comorbidities, such as HIV, which fosters the acquisition of TB (Bamrah, 2013). Many
often use alcohol and/or illicit drugs that impair their judgement (Bamrah, 2013). In
addition, many are often plagued with legal troubles and are in and out of jail. Many
homeless persons have no access to medical care (Bamrah, 2013). Yet even access to
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medical care may not encourage homeless persons to seek treatment for latent TB. A
study in Canada touched on some barriers that homeless persons face despite living in a
country that has universal health coverage. Homeless persons may not be aware that they
are at risk for TB and have had bad experiences within the health care system that prevent
them from seeking care (Malejczyk, 2014). Mental illness is present in a number of
homeless individuals (Shelton et al., 2009). Homeless participants often are malnourished
and often go hungry (Baggett et al., 2010). Amidst these troubles, homeless people face
many challenges in beginning and complying with treatment for TB. There may be a
biological foundation that also predisposes homeless persons to TB; TB genotyping data
posits that homelessness increases the transmission of TB (Malejczyk, 2014). As the
instability of the economy continues, paired with the increase in immigrants to the U.S.
from countries where TB is endemic, TB is a risk for the population at large. Considering
the above factors, and considering how unstable their lives are, a shorter treatment is
more advantageous for homeless people, as it will be easier for them to follow.
It is especially important for homeless persons to be treated for latent TB
considering the substantial financial burden that could result from lengthy, preventable
hospitalizations attributable to TB (Marks, 2000). Since latent TB is largely
asymptomatic, homeless persons are largely unaware that they carry latent TB and may
not seek treatment until they have active symptoms. Thus, any manifestation of TB has
then likely progressed to an advanced, active form, complications may have arisen that
require lengthy hospitalizations, and transmission to others is likely to have occurred. In a
cohort study, more homeless persons than non-homeless persons were incarcerated at the
time of their diagnosis of TB (Marks, 2000). This study also found that, when compared
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to their hospitalized non-homeless counterparts, hospitalized homeless persons were
more likely to have HIV, be substance abusers, and inject drugs. Homeless TB patients
also had a higher rate of hospitalization and a longer median length of stay. Treatment
compliance was higher among hospitalized TB patients than for non-hospitalized
patients.
It is difficult to get a true measure of the number of homeless persons in America
and, in turn, an accurate rate of TB among homeless persons (Haddad, 2005). Many are
not accounted for or are in and out of jail. Others lapse into periods of homelessness
(Bamrah, 2013). The 2013 Bamrah et al. article found that homeless people had a tenfold
increase in TB compared with the general population (36 to 47 out of 100000 homeless
individuals versus 3.6 out of 100000 people in the general population for 2006-2010).
This number is noteworthy, considering that homeless individuals comprise less than ten
percent of the population in the U.S.
Objective
The objective of this analysis is to evaluate factors associated with noncompletion of treatment among homeless participants enrolled in the PREVENT TB trial.
A better assessment of these factors may help to direct prevention strategies in the
homeless population to increase completion of LTBI treatment.
3. METHODS AND PROCEDURES

These analyses examine data collected from the PREVENT TB trial of the TB
Trials Consortium (TBTC), Centers for Disease Control and Prevention, Division of TB
Elimination. The PREVENT TB Trial, “A Study of the Effectiveness and Tolerability of
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Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months
for the Treatment of Latent TB Infection”, used two treatment regimens: 3HP: directly
observed administration of isoniazid and rifapentine given weekly for twelve weeks and
9H, a daily self-administered dose of isoniazid taken for nine months. 9H is the standard
and most common treatment regimen of LTBI. A total of 8, 053 participants were
enrolled in the study. Participants evaluated were infected with M. tuberculosis or were at
high risk of developing TB. They all had the latent TB. Participants were deemed to have
latent TB in any of the following four scenarios: a recent conversion to a positive
tuberculin skin test, HIV positive status with a positive tuberculin skin test, close contact
with a culture confirmed TB patient, or a positive tuberculin skin test with an
accompanying chest radiograph that shows fibrosis. After excluding non-North American
sites, pregnant women, persons less than 18 years of age, and ineligible persons, the
combined cohort consisted of 6, 232 individuals (Figure 1). Only sites within the U.S.
and Canada were examined in this analysis for relative homogeneity of health practices in
the north-American region.

Subjects were assigned to study groups according to simple unrestricted
randomization. In group settings (such as households or homeless shelters), subjects
could be placed on the same regimen as the first person in the group (cluster). That way,
everyone in the cluster received the same treatment, as they were within contact of one
another and are comparable amongst themselves. In this way, only the first person in the
cluster was randomized in the study but everyone within the cluster received treatment.
Randomization was stratified by HIV status and enrolling site. Throughout the course of
the study, participants had a series of clinical evaluations. Participants in the 3HP DOT
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treatment regimen had clinical evaluations at weeks 4, 8, and 12. Participants in the 9H
treatment regimen underwent monthly clinical evaluations. Each clinical evaluation
assessed such items as weight, adverse reactions, new diagnoses or hospitalizations, use
of concomitant medications, and methadone withdrawal. Adverse events were recorded if
their onset was at any time during the study, as well as up to 60 days after administration
of the last study dose. For the 3HP regimen, adherence was measured by therapy records
for the study drugs. For the 9H regimen, adherence was measured by pill count and selfreport.

Factors associated with non-completion were categorized as demographic
(including age, sex, race, ethnicity, country of origin, unemployment, homeless, history
of incarceration, need for an interpreter), clinical (body mass index, HIV status,
concomitant medication use, indication for LTBI treatment, cirrhosis, methadone
treatment), social (alcohol consumption, smoking status, intravenous drug use), or
behavioral (missed visits, treatment regimen, or enrollment site).

The classification of not completing treatment was as follows: in the 3HP
regimen, missing at least one study drug dose within 10 to 16 weeks; in the 9H treatment
regimen, missing thirty doses within 35 to 53 weeks. In addition to not completing
treatment, missing clinic visits were also tracked. Missing an early visit was defined for
the two treatment regimens as follows: missing 1 or more than 1 of the first 3 observed
doses in the 3HP-DOT regimen followed by receiving an observed dose during the
course of the treatment period; in the 9H-SAT regimen missing 1 or more than one of the
first 3 monthly visits, followed by a monthly visit at any time during the treatment period.
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Alcohol abuse was classified as a score of at least 2 on the CAGE questionnaire.
Participants were asked if they currently smoked at the time of enrollment.

All participants provided written informed consent. The study protocol was
reviewed and approved by the institutional review boards at the Centers for Disease
Control and Prevention and at each of the participating clinical sites.
Non-completion of treatment (NCT) proportions were calculated for all potential
factors evaluated. Age was categorized as above or below the median age of the study
population (38 years). Odds ratios (ORs), 95% confidence intervals (CIs), and P values
were calculated for potential risk factors for NCT. All factors with a p-value  0.2, as
well as those that were near significant, in the univariate analysis were included in the
multivariate model, in addition to age and sex. We performed backward elimination to
select statistically significant factors with p-value < 0.05. Univariate and multivariate
analyses were conducted among various factors outlined above using SAS® version 9.3
(SAS Institute, Inc., Cary, North Carolina).

4. RESULTS

The combined cohort for analysis included 6,232 participants (3HP = 3,230 and
9H=3,002) (Figure 1), of which 505 were homeless (8.1%, 3HP = 289, 9H = 216). Most
homeless participants were male (86.7%), born in the U.S. (87.1%), and of African
descent (53.1%). The median age was 46 compared with 36 in the non-homeless group.
Other characteristics associated with homelessness were unemployment, smoking,
alcohol consumption, and use of concomitant medications. Additional demographic
characteristics can be found in Table 1.
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Comparison of demographic factors among homeless participants, stratified by
treatment regimen are shown in Table 2. Most of the factors evaluated in this table shown
to be non-significant. Thus, the distribution of factors among the homeless participants
was similar in both treatment regimens. The table also shows that most homeless
participants in both treatment regimens were more likely to be of African descent
(124/216, 57.41% for the 9H regimen and 144/289, 49.83% for the 3HP regimen) and
have a BMI classifying them as overweight (87/216, 40.28% for the 9H regimen versus
112/289, 38.75% for the 3HP regimen).

Table 3 shows treatment completion among all of the studied participants,
stratified by treatment arm and homelessness. Homeless participants assigned to the 3HP
regimen, were more likely to complete LTBI treatment (227/289, 79%, p<0.001) than
homeless participants assigned to the 9H regimen (132/216, 61%, p<0.001).

Tables 4A and 4B show the reasons for non-completion of treatment by treatment
regimen. In the 9H regimen, the most frequent factor was being lost for more than 3
months (40%), followed by the category classified as ‘other’ (26%) and drug toxicities
(12%). In the 3HP regimen, the most frequent reason for not completing treatment among
homeless persons was the ‘other’ reason (27%), followed by drug toxicities and being
lost for more than 3 months (20%).
Tables 4C and 4D present classification of the “other” reasons presented in Tables
4 A and 4B. For the 9H regimen, incarceration and loss of a participant accounted for the
other reason. This was also the case with the “other” reason in the 3HP regimen. Even
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after classification of the “other” variable, there were still unknown/ missing reasons
within the “other” variable for non-completion of treatment.

Results from a univariate analysis within the homeless population are presented in
Table 5. Participants assigned to the 9H regimen, were more likely not to complete
treatment compared to participants assigned to receive the 3HP regimen (OR: 2.1;
95%CI: 1.4, 3.18; p<0.001). Other factors associated with non-completion of treatment
were contact of a TB case as a reason to receive LTBI treatment (OR: 1.64; 95%CI: 1.04,
2.58; p=0.03) and missing an early clinic visit (OR: 5.3; 95%CI: 2.71, 10.4; p<0.0001).
Some factors were almost significant, such as ethnicity (OR 1.70, 95% CI: 0.96 – 3.01,
p=0.072), birthplace (OR 1.65, 95% CI 0.96 – 2.83, p= 0.07) , and history of
incarceration (OR 1.635, 95% CI 0.97 – 2.12, p = 0.07).

Multivariate analysis is displayed in Table 6. The multivariate model assesses the
association of certain factors with the outcome of non-completion of LTBI treatment
while controlling for other factors. Factors found to be statistically associated with
treatment non-completion among homeless were: the 9H regimen (OR: 2.11; 95%CI:
1.40, 3.18; p=0.0003), born in non-US compared to those who were born in US countries
(OR: 1.96; 95%CI: 1.1, 3.48; p=0.0220), history of incarceration (OR: 1.69 ; 95%CI:
1.11, 2.57: p=0.0148), and missing an early clinic visit compared to those who did not
missed a clinic visit (OR: 4.57; 95% CI: 2.46, 8.49: p<0.0001). Similar results were
obtained when the same analysis was applied to the population selected by the first
participant enrolled in a cluster. (Table S5).
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Table 7 presents the homeless participants stratified by regimen and site. Sites
located in Texas and Washington State had the highest proportion of enrollment of
homeless participants. Table 8 shows the sizes of the different clusters enrolled, stratified
by homeless status. The largest cluster was the one with 31 participants (29 in the 3HP
and 2 in the 9H regimen).

Table 9 shows the size of clusters among only the homeless population, stratified
by treatment regimen. The largest cluster was the one with 29 participants enrolled, all in
the 3HP regimen.

Table S1 presents characteristics of the first participant enrolled in a cluster,
stratified by homeless status. Homeless participants were more likely to be male (84.9%),
born in the U.S. (87.3%), being African descent (58.3%) and be of non-Hispanic origin
(89%). The median age in the homeless population was 46 compared to 37 in the nonhomeless population (p<0.001). They were also more likely to be unemployed, being a
current smoker and report alcohol consumption at the time of enrollment (p<0.001).

Table S2 details the characteristics of the clustered homeless participants,
stratified by treatment regimen. Most of the factors evaluated were equally distributed
between both regimens indicating that the effects of randomization were still present after
some exclusions were done to define the study population of this study.

Table S3 shows the univariate analyses among the clustered homeless
participants. The most significant factor was missed an early clinic visit associated with
non-completion of treatment (OR: 5.3; 95%CI: 2.71, 10.4; p<0.001). Other factors
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associated with non-completion of treatment were being Hispanic (OR: 2.1; 95%CI: 1.13,
3.98; p=0.02), born in a non-US country (OR: 2.1; 95%CI: 1.14, 3.70; p=0.02), contact of
a TB case as the reason to receive LTBI treatment (OR: 1.64; 95% CI: 1.04, 2.58;
p=0.03), and missed an early clinic visit (OR: 5.3; 95%CI: 2.71, 10.4; p<0.001),

Table S4 shows the multivariate analyses for non-completion of treatment among
the first participant enrolled in the cluster. Among the clustered homeless participants, the
most significant factor associated with non-completion of treatment was missed early
clinic visit (OR: 5.2; 95%CI: 2.55, 10.46; p<0.001), followed by born in the US
compared to those born in non-U.S. countries (OR: 2.81; 95%CI: 1.48, 5.35; p=0.0016),
receiving 3HP compared to 9H regimen (OR: 2.2; 95%CI: 1.41, 3.53; p=0.0006), and
history of incarceration (OR: 2.1; 95%CI: 1.28, 3.32; p=0.0029).

5. DISCUSSION

The most significant factor in the multivariate analysis for non-completion of
treatment in the homeless population was missing an early clinic visit (OR: 4.57, 95% CI:
2.46- 8.49; p<0.0001) after controlling for other factors. This result is consistent when
the analysis was limited to the first participant enrolled in a cluster. This finding follows
logic, as it questions the compliance of the participants. Monitoring missed clinic visits is
important to ensure that treatment is being followed as prescribed and to monitor for any
potential adverse events. The shorter 3HP regimen was also associated with better
treatment compliance (OR: 2.1; 95% CI: 1.42- 3.18; p=0.0003). Thus, homeless
participants in the 9H regimen were 2.13 times more likely not to complete treatment
compared to 3HP. The 3HP regimen is more advantageous than 9H for homeless persons,
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as it requires less of a time commitment from them. Incarceration also plays a role in
determining treatment compliance. A homeless person with history of incarceration may
have other social factors that may prevent him or her from complying with treatment. In
addition, there is the possibility that a homeless person with history of incarceration may
interrupt treatment due to a new incarceration. The interruption in treatment is
problematic on many levels. Although alcohol use was not significantly associated with
non-completion of treatment in the univariate analysis, alcohol use may impair the
judgment of a person and also may contribute to hepatotoxicity with treatment
medications.

Nuzzo et al. found that LTBI treatment completion was highest among refugees
(296/333, 89%) and also found some evidence that treatment completion was higher
among those persons who received a shorter treatment regimen. However, this finding
was not statistically significant in this analysis after adjusting for other factors.

Our study found that many homeless persons either used or abused alcohol (use:
223/501=44.2%, abuse:181/501=35.8%). A report on homelessness (Haddad, 2005)
found that excessive alcohol use was greater among homeless than non-homeless
persons. This is concerning, considering that the drugs used in this study may cause
hepatotoxicity. Hepatotoxicity is exacerbated by alcohol use, especially by alcohol abuse.
This report also found that more non-homeless persons (84%) completed TB treatment
compared to homeless persons (77%) which may be a factor for increasing the
transmission of M. tuberculosis in this population.
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The findings in these analyses are supported by a similar study that examined
both treatment initiation and continuation of LTBI treatment. This study found that most
participants were foreign-born and a racial/ethnic minority and those more likely to
initiate treatment had a history of incarceration (Goswami, 2012). The study also showed
that treatment completion was more likely to occur among non-smokers. This study noted
that initiating, rather than completing, LTBI treatment was more challenging.

The burden of TB among males, particularly homeless males, is supported by a
cross-sectional Korean study (Lee, 2013). Out of the 313 homeless participants, 309 of
them were male. This study also supported the fact that homeless persons carry a
disproportionate burden of TB when compared to the general population.

As our study favors combination therapy for the treatment of LTBI in the
homeless population, the administration of the combination therapy under directly
observed therapy may increase compliance. Increasing LTBI treatment completion in
persons at risk of developing TB is an important component of TB control/elimination
strategy.

Limitations

One limitation of the study was not examining the effect of certain comorbidities
such as diabetes on examining treatment completion. Studies are emerging that show the
link between Type II diabetes and TB (Martínez-Aguilar et al., 2015); (Restrepo &
Schlesinger, 2014). This is noteworthy, as most participants in this study had a BMI
categorizing them as overweight and most homeless participants were Africa-American.
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Type II diabetes is a particular burden among those with a high BMI as well as AfricanAmericans, so its distribution among participants in this study would have been
compelling to explore.

Injection drug use as well as methadone use were self-reported. Due to the
sensitive nature of these questions, participants may not have been forthcoming with this
information. This may have resulted in misclassification bias.

Another limitation is that the study assumed that those who were assigned to the
9H regimen took their doses as prescribed without being under the direct observation of a
clinician. The counting of 9H doses relied on the participant’s report. DOT completion
reporting is likely to be more reliable. Self-reported completion might overestimate actual
completion, causing the treatment completion differences between treatment regimens
reported in this study to be conservative underestimates.

Among both the homeless and non-homeless participants, quite a number of them
have an unknown HIV status (159/505, 31.49% among homeless participants versus
2839/5727, 49.57% among non-homeless participants). Many characteristics of homeless
persons that place them at risk for TB are also risk factors for HIV. Therefore, it would
be beneficial to obtain an HIV test on these participants and initiate anti-retroviral
therapy, if they are HIV positive. HIV status is especially important considering it is a
known risk factor for TB. In one study, forty percent of incident TB cases were
seropositive for HIV (Moss, 2000).
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Less than ten percent of the study participants enrolled in the PREVENT TB trial
were homeless (6%), which may limit these analyses. However, the number of homeless
persons in the study are comparable with estimates of homeless persons in the United
States of 842,000 people, or one percent of the population. (National Coalition for the
Homeless, http://www.nationalhomeless.org/factsheets/How_Many.html).

6. CONCLUSION

Early, effective treatment for LTBI among high risk groups such as homeless
persons is challenging but in the best interest of the general public. Better prevention
strategies and coordination among different sectors of public health need to be
implemented in order to ensure compliance of treatment. Unique approaches need to be
implemented towards homeless persons so they understand the gravity of being treated
for latent TB. The PREVENT TB trial, as well as other studies, have supported better
compliance rates with shorter LTBI treatment regimens. Therefore, every effort should be
made to offer shorter treatment regimens to homeless persons and those persons in whom
compliance may be challenging. A more seamless treatment regimen should also be
available for homeless persons with history of incarceration. Homelessness as well as
incarceration have high recidivism rates so follow-up is important in those persons who
vacillate between the two states. Homeless and incarcerated individuals live on the
fringes of society so it is a particular challenge for people to invest in them. Focused
strategies that encourage treatment compliance will surely make the elimination of TB
more of a possibility.
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Figure 1. Flow Chart of Participants Evaluated for Factors Associated with Noncompletion of Latent TB Infection Treatment in Homeless Participants Enrolled in
The PREVENT TB Study – North American Sites (from the Tuberculosis Trials
Consortium)

Participants enrolled in the
PREVENT TB Study
from 05 June 2001 to 15 February 2008
n = 8,053

Non-North American sitesa (n = 920)
n = 7,133
Persons < 18 years of ageb (n = 592)
n = 6,541
Pregnancies (n = 114)
n = 6,427
Ineligibles c (n = 195)
Combined cohort for analysis
(n = 6,232) d
3HP (n = 3,230) 9H (n = 3,002)

Abbreviation: AE, adverse event
a
This analysis includes enrolling sites from U.S. and Canada. Enrolling sites from Brazil and Spain were
excluded.
b
This analysis considers adults age 18 or older.
c
PREVENT TB Study reasons for ineligibility: source case resistant isoniazid/rifampin (50%), source case culture
negative (31%), other (19%). Exclusion criteria: a) current confirmed TB, b) suspected TB, c) TB
resistant to isoniazid or rifampin in the source case, d) history of treatment for >14 consecutive days with a
rifamycin or
>30 consecutive days with isoniazid during the previous 2 years, e) documented history of completing adequate
treatment for active TB or latent M. TB infection in a HIV-seronegative person, f) history of sensitivity/intolerance
to isoniazid or rifamycins, g) serum aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) if
AST was determined, h) pregnant or lactating females, i) persons currently receiving or planning to receive HIV-1
therapy
within 90 days after enrollment, or j) weight < 10.0 kg.
d
Reasons for LTBI treatment (not-mutually exclusive): contact of infectious TB case (n = 4,156), tuberculin skin
test converter (n = 2,205), HIV positive (n = 140), and fibrosis (n = 181).
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Table 1. Demographics Characteristics Among Homeless and Non-Homeless
Participants in the United States and Canadian Sites in the PREVENT TB Trial
(N= 6232)
Factor
Homeless
Non-homeless
p-value
n=505 (%)
n= 5727 (%)
Sex
<0.001
Male
438 (86.73)
3056 (53.36)
Female
67 (13.27)
2671 (46.64)
Age-years
<0.001 a
Median
46
36
Interquartile range
40, 52
27, 47
Siteb
<0.0001
Other
488 (96.63)
5398 (94.26)
sites
17 (3.37)
329 (5.74)
Site
70
Birthplace in the U.S.
<0.001
Yes
440 (87.13)
2050 (35.80)
No
65 (12.87)
3677 (64.20)
Race
<0.001
African descendent
268 (53.07)
1361 (23.76)
Asian
11 (2.18)
869 (15.17)
White
186 (36.83)
3283 (57.32)
Other d
40 (7.92)
214 (3.74)
Ethnicity
<0.001
Hispanic
56 (11.09)
2546 (44.46)
Non-Hispanic
449 (88.91)
3181 (55.54)
BMI-numeric
0.5223 a
Median
27
27
Interquartile range
(24,31)
(24,31)
BMI Category
0.1701
<18.5
9 (1.78)
95 (1.66)
18.5 – 24.9
146 (28.91)
1639 (28.62)
25-29.9
199 (39.41)
2022 (35.31)
>30
151 (29.90)
1971 (34.42)
Education Category
<0.001
8th grade or less
44 (8.71)
1084 (18.93)
8th grade to some college
432 (85.54)
3514 (61.36)
College degree or greater
29 (5.74)
1129 (19.71)
e
History of incarceration
<0.001
Yes
194 (38.42)
199 (3.47)
No
311 (61.58)
5528 (96.53)
Unemployment
<0.001
Yes
331 (65.54)
444 (7.75)
No
174 (34.46)
5283 (92.25)
Latent TB contact
42

Factor
Yes
No

Homeless
n=505 (%)
348 (68.91)
157 (31.09)

Non-homeless
n= 5727 (%)
3808 (66.49)
1919 (33.51)

0.2689
<0.001c

Latent TB fibrosis
Yes
No
Latent TB HIV positive
Yes
No
Latent TB TST converter
Yes
No
HIV status
Positive
Negative
Unknown
Smoking at enrollment
Yes
No
f
Alcohol consumption
use
abuse
no
Injection drug use
Yes
No
Methadone treatment
Yes
No
Use of concomitant
medications
Yes
No
Use of a translator
Yes
No
Liver disease
Yes
No

p-value

1 (0.20)
504 (99.80)

180 (3.14)
5547 (96.86)
<0.001

33 (6.53)
472 (93.47)

107 (1.87)
5620 (98.13)

210 (41.58)
295 (58.42)

1995 (34.83)
3732 (65.17)

0.0024

<0.001
36 (7.13)
310 (61.39)
159 (31.49)

112 (1.96)
2776 (48.47)
2839 (49.57)
<0.001

370 (73.27)
135(26.73)

1540 (26.89)
4187 (73.11)
<0.001g

223 (44.16)
181 (35.84)
101(20)

2675 (46.71)
302 (5.27)
2750 (48.02)

111 (21.98)
394 (78.02)

156 (2.72)
5571 (97.28)

25 (4.95)
480 (95.05)

112 (1.96)
5615 (98.04)

288 (57.03)
217 (42.97)

2764 (48.26)
2963 (51.74)

<0.001

<0.001

0.0002

<0.001
25 (4.95)
480 (95.05)

1616 (28.22)
4111 (71.78)

101 (20)
404 (80)

151 (2.64)
5576 (97.36)

<0.001

Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900
mg)
plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid; LTBI:
latent
TB infection. HIV: human immunodeficiency virus. BMI: body mass index. TST: tuberculin skin test.
a
Median Two-Sample Test using the proc npar1way SAS procedure.
b
The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.

43

Fisher’s exact test
Includes North American Indian and other participants in the United States and Canada.
e
History of residing within a correctional institution for ≥ 1 month before enrollment.
f
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse:
score of ≥2 on the CAGE questionnaire.
g
Mantel-Haenszel Chi-Square
c

d
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Table 2. Demographic Characteristics of Homeless Participants in the PREVENT
TB Trial, Stratified by Treatment Regimen (N=505)
Factor
Treatment
Treatment
p-value
Regimen 9H SAT
Regimen 3HP
n=216
DOT
n=289
Sex
0.1566
Male
182 (84.26)
256 (88.58)
Female
34 (15.74)
33 (11.42)
Age-years
0.5916a
Median
45
47
Interquartile range
40,53
40,52
Birthplace in the U.S.
0.1627
Yes
183 (84.72)
257 (88.93)
No
33 (15.28)
32 (11.07)
Race
<0.001b
African descendent
124 (57.41)
144 (49.83)
Asian
7 (3.24)
4 (1.38)
White
81 (37.50)
105 (36.33)
Otherc
4 (1.85)
36 (12.46)
Ethnicity
0.3827
Hispanic
27 (12.50)
29 (10.03)
Non-Hispanic
189 (87.50)
260 (89.97)
BMI
0.0284a
Median
26
28
Interquartile range
(23, 29)
(24, 32)
BMI category
<0.001b
<18.5
7 (3.24)
2 (0.69)
18.5 – 24.9
72 (33.33)
74 (25.61)
25-29.9
87 (40.28)
112 (38.75)
>30
50 (23.15)
101 (34.95)
Education category
0.1343
8th grade or less
23 (10.65)
21 (7.27)
8th grade to some
177 (81.94)
255 (88.24)
college
16 (7.41)
13 (4.50)
College degree or
greater
History of
0.2690
d
incarceration
77 (35.65)
117 (40.48)
Yes
139 (64.35)
172 (59.52)
No
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Factor

Treatment
Regimen 9H SAT
n=216

Treatment
Regimen 3HP
DOT
n=289

Unemployment

p-value

0.7655
Yes
No

140 (64.81)
76 (35.19)

191 (66.09)
98 (33.91)

Yes
No

137 (63.43)
79 (36.57)

211 (73.01)
78 (26.99)

Latent TB contact

0.0213
0.5723b

Latent TB fibrosis
Yes
No
Latent TB HIV positive
Yes
No
Latent TB TST
converter
Yes
No
HIV status
Positive
Negative
Unknown
Smoking at Enrollment
Yes
No
Alcohol Consumption e
Use
Abuse
No

0 (0)
216 (100)

1 (0.35)
288 (99.65)

19 (8.80)
197 (91.20)

14 (4.84)
275 (95.16)

0.0754

0.8298
91 (42.13)
125 (57.87)

119 (41.18)
170 (58.82)
0.3206

19 (8.80)
126 (58.33)
71 (32.87)

17 (5.88)
184 (63.67)
88 (30.45)

157 (72.69)
59 (27.31)

213 (73.70)
76 (26.30)

0.7983
0.0569f
92 (42.59)
68 (31.48)
56 (25.93)

131 (45.33)
113 (39.10)
45 (15.57)

Injection drug use
Yes
No
Methadone treatment
Yes
No
Use of a translator
Yes
No
Liver disease
Yes
No

0.5837
50 (23.15)
166 (76.85)

61 (21.11)
228 (78.89)

17 (7.87)
199 (92.13)

8 (2.77)
281 (97.23)

13 (6.02)
203 (93.98)

12 (4.15)
277 (95.85)

51 (23.61)
165 (76.39)

50 (17.30)
239 (82.70)

0.0089

0.3388

0.0794
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Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.
TST: tuberculin skin test. 3HP-DOT: 3 months of directly observed, once-weekly rifapentine (maximum
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. TST:
tuberculin skin test.
a
Median Two-Sample Test
b
Fisher’s exact test
c
Includes North American Indian and other participants in the United States and Canada.
d
History of residing within a correctional institution for ≥ 1 month before enrollment.
e
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse: score of ≥2 on the CAGE questionnaire.
f
Mantel-Haenszel Chi-Square

Table 3. LTBI Treatment Completion, Stratified by Homelessness and by
Treatment Regimen (n=6232)
Treatment
Homeless (n=505)
Non-homeless (n=5727)
completion
p-value
p-value
3HP
9H
3HP
9H
n=289 (%) n=216 (%)
n=2941 (%) n=2786 (%)
<0.0001
<0.0001
227 (79)
132 (61)
2435 (83)
2032 (73)
Completed
Did not
complete

62 (21)

84 (39)
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506 (17)

754 (27)

Table 4A. Reasons for not Completing LTBI Treatment, Stratified by Homelessness
Status Among Participants Assigned to the 9H Regimen (n=838)
Reason category –no. (%)

Homeless
n=82
33 (40.24)
21 (25.61)
10 (12.20)
9 (10.98)
4 (4.88)
3(3.66)
2 (2.44)
0(0)
2

Lost for more than 3 months
Other
Drug toxicities
Patient refused therapy
Patient withdrew consent
Out of window
Prescription cancelled by MD
Patient died
Missing

Non-Homeless
n=750
243 (32.40)
97 (12.93)
119 (15.87)
161 (21.47)
57 (7.60)
33 (4.40)
38 (5.07)
2 (0.27)
4

Table 4B. Reasons for not Completing Treatment, Stratified by Homelessness
Status Among Participants Assigned to the 3HP Regimen (n=568)
Reason category –no. (%)
Homeless
Non-Homeless
n=59
n=490
Other
16 (27.12)
36 (7.35)
Drug toxicities
12 (20.34)
169 (34.49)
Lost for more than 3 months
12 (20.34)
44 (8.98)
Patient refused therapy
11 (18.64)
172 (35.10)
Out of window
4 (6.78)
13 (2.65)
Prescription cancelled by MD
3(5.08)
11 (2.24)
Patient withdrew consent
1 (1.69)
45 (9.18)
Missing
3
16
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Table 4C. Classification of “Other” Reason for Non-completion of Treatment in the
9H Regimen, Stratified by Homeless Status (n=118)
Reason

Homeless (n=21)

Non-homeless (n=97)

Incarceration
Moved
Military deployment
Lost
Tx stopped
School/ work conflicts
Legal trouble
Unable to obtain meds in
rehab
Non-compliant
MD wants to remove
patient from study
No reason

6
3
0
0
0
0
0
0

9
20
5
3
4
3
1
1

0
0

1
1

12
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Table 4D. Classification of “Other” Reason for Non-completion of Treatment in the
3HP Regimen, Stratified by Homeless Status (n=52)
Reason

Homeless (n=16)

Non-homeless (n=36)

Incarceration
Moved
Lost
Non-compliant
VISA expired
Fleeing to Mexico due to
legal trouble
Unknown

3
1
1
0
0
0

6
9
1
2
1
1

11

16
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Table 5. Factors Associated with Non-completion of LTBI Treatment in Homeless
Participants – Univariate Analysis (n=505)
Factor
Treatment
Regimen
Age
Sex
Race

Siteb
Ethnicity

HIV Status

Birthplace
Body Mass
Index

Education

Incarcerationc
Unemployed
Alcohol
Consumptiond

3HP-DOT (n=216)
Ref.
9H-SAT (n=289)
<38 (n=89)
≥38 (n=416) Ref.
Female (n=67) Ref.
Male (n=438)
White (n=186) Ref.
African descendent
(n=268)
Asian (n=11)
Othera (n=40)
Site 70 (n=17) Ref.
Other sites (n=488)
Non-Hispanic
(n=449) Ref.
Hispanic (n=56)
Negative (n=310)
Ref.
Positive (n=36)
Unknown (n=159)
Non-U.S (n=65)
U.S. (n=440) Ref.
Underweight (n=9)
Normal (n=146) Ref.
Overweight (199)
Obesity (n=151)
≤8th grade (n=44)
8th grade through
some college
(n=432)
≥college degree
(n=29) Ref.
Yes (n=194)
No (n=311) Ref.
Yes (n=331)
No (n=174) Ref.
No (n=101) Ref.
Use (n=223)
Abuse (n=181)

NCT
(%)
21.45
38.89

Odds
Ratio
Ref.
2.33

Confidence
Interval
Ref.
1.57-3.45

P-value

32.58
28.13
25.37
29.45
32.80
25.37
27.27
35

1.24
Ref.
Ref.
1.23
Ref.
0.70

0.76-2.02
Ref.
Ref.
0.68-2.21
Ref.
0.46-1.05

0.40
Ref.
Ref.
0.49
Ref
0.085

0.77
1.10
Ref.
0.98
Ref.

0.20-3.00
0.53-2.26
Ref.
0.34-2.82
Ref.

0.705
0.788
Ref.
0.96
Ref.

1.70
Ref.
1.19
0.85

0.96-3.01
Ref.
0.57-2.47
0.55-1.31

0.072
Ref.
0.65
0.46

1.65
Ref.
0.99
Ref.
0.88
0.55
1.23

0.96-2.83
Ref.
0.24-4.13
Ref.
0.55-1.38
0.33-0.93
0.44-3.44

0.07
Ref.
0.99
Ref.
0.57
0.03
0.70

27.59

1.06
Ref.

0.46-2.45
Ref.

0.90
Ref.

33.51
26.05
28.10
30.46
32.60
24.22
32.67

1.635
Ref.
0.87
Ref.
Ref.
0.66
1.00

0.97-2.12
Ref.
0.60 – 1.33
Ref.
Ref.
0.39-1.10
0.59-1.68

0.07
Ref.
0.58
Ref.
Ref.
0.11
0.99

29.41
28.89
27.62
39.29
29.68
33.33
26.42
38.46
27.50
33.33
33.56
30.65
21.85
31.82
28.70
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Ref.
<0.001

Factor
Intravenous
drug user ever
Smoking at
Enrollment
Use of
Methadone
Concomitant
medications
LTBI for
contact TB
LTBI for TST
converter
LTBI fibrosis

No (n=394) Ref.
Yes (n=111)
No (n=135) Ref.
Yes (n=370)
No (n=480) Ref.
Yes (n=25)
No (n=217) Ref.
Yes (n=288)
No (n=157) Ref.
Yes (n=348)
No (n=295) Ref.
Yes (n=210)
No (n=504) Ref.
Yes (n=1)

NCT
(%)
29.19
27.93
28.15
29.19
28.75
32
31.80
26.74
22.93
31.61
31.19
25.71
28.97
0

LTBI for HIV
infection
Chronic Liver
Disease
Missed clinic
visite

No (n=472) Ref.
Yes (n=33)
Yes (n=86)
No (331) Ref.
No (n=453) Ref.
Yes (n=52)

29.03
27.27
31.68
28.22
25.17
61.54

Odds
Ratio
Ref.
0.94
Ref.
1.05
Ref.
1.17
Ref.
0.78
Ref.
1.55
Ref.
0.76
Ref.
<0.001
Ref.
0.92
1.18
Ref.
Ref.
4.76

Confidence
Interval
Ref.
0.59-1.50
Ref.
0.68-1.63
Ref.
0.49-2.77
Ref.
0.53-1.15
Ref.
1.01-2.40
Ref.
0.51-1.13
Ref.
<0.001>999.999
Ref.
0.42-2.02
0.74-1.89
Ref.
Ref.
2.62-8.65

P-value
Ref.
0.80
Ref.
0.82
Ref.
0.73
Ref.
0.21
Ref.
0.05
Ref.
0.18
Ref.
0.99
Ref.
0.83
0.49
Ref.
Ref.
<0.0001

Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900
mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid;
LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. TST: tuberculin
skin test. NCT: non-completion of treatment
a
Includes North American Indian and other participants in the United States and Canada.
b
The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.
c
History of residing within a correctional institution for ≥ 1 month before enrollment.
d
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse: score of ≥2 on the CAGE questionnaire.
e
Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly clinic
visits for the 9H regimen, followed by a DOT or a monthly visit, respectively.
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Table 6. Factors Associated with Non-completion of LTBI Treatment Among
Homeless Participants – Multivariate Analysis (N=505)
Factor
NCT (%)
Odds Ratio
p-value
(95% CI)
Treatment
3HP (n=216) Ref. 12.28
Ref.
Ref.
regimen
9H (n=289)
16.63
2.11 (1.40,
0.0003
3.18)
Birthplace in the
Non-US (n=65)
23.96
1.96 (1.11,
0.0220
US
US (n=440) Ref.
4.95
3.48)
Ref.
Ref.
a
Incarceration
Yes (n=194)
12.87
1.69 (1.11,
0.0148
No (n=311) Ref.
16.04
2.57)
Ref.
Ref.
Missed clinic visit No (n=453) Ref.
22.57
4.57 (2.46,
<0.0001
b
Yes (n=52)
6.34
8.49)
Ref.
Ref.
Abbreviations: NCT: non-completion of treatment; 3HP-DOT, 3 months of directly observed, onceweekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9
months of daily self-administered isoniazid
a
History of residing within a correctional institution for ≥ 1 month before enrollment.
b
Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly
clinic visits for the 9H regimen, followed by a DOT or a monthly visit, respectively.
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Table 7. Homeless Participants Stratified by Regimen and Site (n = 505)
Site

3HP
n=289 (%)

9H
n=216 (%)

G (n=181)
L (n=78)
C (n=57)
J (n=40)
N (n=42)
V (n=17)
D (n=12)
T (n=7)
U (n=14)
P (n=13)
E (n=9)
R (n=6)
B (n=7)
H (n=2)
O (n=8)
A (n=1)
F (n=4)
I (n=2)
K (n=2)
M (n=1)
Q (n=1)
S (n=1)
Total = 505

110 (21.78)
55 (10.89)
30 (5.94)
25 (4.95)
17 (3.37)
9 (1.78)
7 (1.39)
6 (1.19)
6 (1.19)
5 (0.99)
4 (0.79)
3 (0.59)
2 (0.40)
2 (0.40)
2 (0.40)
1 (0.20)
1 (0.20)
1 (0.20)
1 (0.20)
1 (0.20)
1 (0.20)
0 (0)
289 (8.94)

71 (14.06)
23 (4.55)
27 (5.35)
15 (2.97)
25 (4.95)
8 (1.58)
5 (0.99)
1 (0.20)
8 (1.58)
8 (1.58)
5 (0.99)
3 (0.59)
5 (0.99)
0 (0)
6 (1.19)
0 (0)
3 (0.59)
1 (0.20)
1 (0.20)
0 (0)
0 (0)
1 (0.20)
216 (7.20)

Site key: A=12, B=13, C=14, D=15, E=16, F=17, G=20, H=21, I=22, J=23, K=24, L=26, M=27, N=28, O=53,
P=54, Q=58, R=61, S=62, T=63, U=66, V=70
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Table 8. Clusters of Participants Enrolled in the PREVENT TB Trial,
Stratified by Homelessness Status (N=6232)
Homeless
Non-Homeless
(n=505)
(n=5727)
Clusters
1
399 (79.01)
4138 (72.25)
2
19 (3.76)
653 (11.40)
3
5 (0.99)
284 (4.96)
4
12 (2.38)
220 (3.84)
5
7 (1.39)
111 (1.94)
6
0 (0)
63 (1.10)
7
0 (0)
46 (0.80)
8
1 (0.20)
42 (0.73)
9
0 (0)
9 (0.16)
10
7 (1.39)
23 (0.40)
11
12 (2.38)
51 (0.89)
12
0 (0)
24 (0.42)
13
0 (0)
26 (0.45)
14
0 (0)
7 (0.12)
19
14 (2.77)
5 (0.09)
23
0 (0)
23 (0.40)
31
29 (5.74)
2 (0.03)

54

Table 9. Clusters of Homeless Participants Enrolled in the
PREVENT TB Trial Stratified by Treatment Regimen (N=505)
Cluster
3HP (n=289)
9H (n=216)
1
200 (69.20)
199 (92.13)
2
14 (4.84)
5 (2.31)
3
5 (1.73)
0 (0)
4
6 (2.08)
6 (2.78)
5
2 (0.69)
5 (2.31)
8
0 (0)
1 (0.46)
10
7 (2.42)
0 (0)
11
12 (4.15)
0 (0)
19
14 (4.84)
0 (0)
31
29 (10.03)
0 (0)
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Table S1. Demographic Characteristics Among First Participants Enrolled in a
Cluster, Stratified by Homeless Status (N=5173)
Factor
Homeless
Non-Homeless
n=417 (%)
n=4756 (%)
Sex
Male
354 (84.89)
2487 (52.29)
Female
63 (15.11)
2269 (47.71)
Age-years
Median
46
37
Interquartile range
40,52
28,47
Site b
Site 70
16 (3.84)
305 (6.41)
Other sites
401 (96.16)
4451 (93.59)
Birthplace in the U. S.
Yes
364 (87.29)
1879 (39.51)
No
53 (12.71)
2877 (60.49)
Race
African descendent
243 (58.27)
1233(25.93)
Asian
10 (2.40)
708 (14.89)
White
154 (36.93)
2635 (55.40)
Other d
10 (2.40)
180 (3.78)
Ethnicity
Hispanic
45 (10.79)
1912 (40.20)
Non-Hispanic
372 (89.21)
2844 (59.80)
BMI
Median
27
27
Interquartile range
(24, 30)
(24, 31)
BMI Category
<18.5
7 (1.68)
76 (1.60)
18.5 – 24.9
123 (29.50)
1366 (28.72)
25-29.9
169 (40.53)
1669 (35.09)
>30
118 (28.30)
1645 (34.59)
Education category
8th grade or less
37 (8.87)
751 (15.79)
th
8 grade to some college
355 (85.13)
2937 (61.75)
College degree or greater
25 (6)
1068 (22.46)
History of incarceration e
Yes
160 (38.37)
179 (3.76)
No
257 (61.63)
4577 (96.24)
Unemployment
Yes
269 (64.51)
385 (8.10)
No
148 (35.49)
4371 (91.90)
Latent TB-contact
Yes
261 (62.59)
2844 (59.80)
No
156 (37.41)
1912 (40.20)
Latent TB Fibrosis
57

p-value
<0.001
<0.001a

<0.001

<0.001

<0.001

<0.001
0.3005a

0.0518

<0.001

<0.001

<0.001

0.2645
<0.001b

Factor
Yes
No

Homeless
n=417 (%)
1 (0.24)
416 (99.76)

Non-Homeless
n=4756 (%)
177 (3.72)
4579 (96.28)

Latent TB – HIV positive

p-value

<0.001
Yes
No

33 (7.91)
384 (92.09)

105 (2.21)
4651 (97.79)

Yes
No

186 (44.60)
231 (55.40)

1913 (40.22)
2843(59.78)

Latent TB –TST converter

0.0806

HIV Status
Positive
Negative
Unknown
Smoking at Enrollment
Yes
No
f
Alcohol Consumption
use
abuse
no
Injection Drug Use
Yes
No
Methadone treatment
Yes
No
Use of concomitant
medications
Yes
No
Use of a translator
Yes
No
Liver disease
Yes
No

<0.001
35 (8.39)
246 (58.99)
136 (32.61)

108 (2.27)
2359 (49.60)
2289 (48.13)
<0.001

304 (72.90)
113 (27.10)

1306 (27.46)
3450 (72.54)
<0.001g

187 (44.84)
141 (33.81)
89 (21.34)

2338 (49.16)
245 (5.15)
2173 (45.69)

97 (23.26)
320 (76.74)

148 (3.11)
4608 (96.89)

<0.001

<0.001
24 (5.76)
393 (94.24)

110 (2.31)
4646 (97.69)
0.0222

236 (56.59)
181 (43.41)

2414 (50.76)
2342 (49.24)

21 (5.04)
396 (94.96)

1150 (24.18)
3606 (75.82)

86 (20.62)
331 (79.38)

136 (2.86)
4620 (97.14)

<0.001

<0.001

Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.
TST: tuberculin skin test. 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. TST:
tuberculin skin test. A cluster represents a group setting; clustered participants represent the first person in a
cluster. This first person underwent randomization and is representative of all participants in the cluster.
a

Median Two-Sample Test using the proc npar1way SAS procedure.
The variable site was categorized arbitrarily taking site with the highest number (70) as the reference
c
Fisher’s exact test
b
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d

Includes North American Indian and other participants in the United States and Canada.
History of residing within a correctional institution for ≥ 1 month before enrollment.
f
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse: score of ≥2 on the CAGE questionnaire.
g
Mantel-Haenszel Chi-Square
e
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Table S2. Demographic Characteristics of the First Homeless Participants Enrolled
in a Cluster, Stratified by Treatment Regimen (N= 417)
Factor

Treatment Regimen
9H SAT
n=204 (%)

Treatment
Regimen
3HP DOT
n=213 (%)

203 (99.5)
1 (0.50)

209 (98.12)
4 (1.88)

Cluster

p-value

0.18
Yes
No

Sex

0.5510
Male
Female

171 (83.82)
33 (16.18)

183 (85.92)
30 (14.08)

Age – years
Median
Interquartile range
Birthplace in the U.S.
Yes
No
Race
African descendent
Asian
White
Otherc
Ethnicity
Hispanic
Non-Hispanic
BMI
Median
Interquartile Range
BMI Category
<18.5
18.5 – 24.9
25-29.9
>30
Education category
8th grade or less
th
8 grade to some
college
College graduate or
greater
History of
incarcerationd
Yes
No

0.7358a
45.5
40.5, 52.5

47
40, 52
0.2311

174 (85.29)
30 (14.71)

190 (89.20)
23 (10.80)
0.8330b

120 (58.82)
6 (2.94)
74 (36.27)
4 (1.96)

123 (57.75)
4 (1.88)
80 (37.56)
6 (2.82)

24 (53.33)
180 (48.39)

21 (46.67)
192 (51.61)

0.5307
0.5944a

26
(23, 29)

27
(24, 32)
0.0208b

6 (2.94)
68 (33.33)
83 (40.69)
47 (23.04)

1 (0.47)
55 (25.82)
86 (40.38)
71 (33.33)
0.1011

22 (10.78)
166 (81.37)
16 (7.84)

15 (7.04)
189 (88.73)
9 (4.23)

0.5096
75 (36.76)
129 (63.24)

85 (39.91)
128 (60.09)
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Factor

Treatment Regimen
9H SAT
n=204 (%)

Treatment
Regimen
3HP DOT
n=213 (%)

Unemployment

p-value

0.9343
Yes
No

132 (64.71)
72 (35.29)

137 (64.32)
76 (35.68)

Yes
No
Latent TB fibrosis
Yes
No
Latent TB HIV
positive
Yes
No
Latent TB TST
converter
Yes
No
HIV Status
Positive
Negative
Unknown
Smoking at
Enrollment
Yes
No
Alcohol
Consumptione
Use
Abuse
No

125 (61.27)
79 (38.73)

137 (64.32)
76 (35.68)

Latent TB contact

0.5869

0.5108e
0 (0)
204 (100)

1 (0.47)
212 (99.53)

19 (9.31)
185 (90.69)

14 (6.57)
199 (93.43)

89 (43.63)
115 (56.37)

97 (45.54)
116 (54.46)

19 (9.31)
119 (58.33)
66 (32.35)

17 (7.98)
139 (65.26)
57 (26.76)

0.3000

0.6945

0.3453

0.4696
152 (74.51)
52 (25.49)

153 (71.83)
60 (28.17)
0.1692f

88 (43.14)
65 (31.86)
51 (25)

99 (46.48)
76 (35.68)
38 (17.84)
0.8614b

Injection drug use
Yes
No
Unknown

Methadone treatment
Yes
No

49 (24.02)
155 (75.98)
0 (0)

48 (22.54)
164 (77)
1 (0.47)

0.0270
17 (8.33)
187 (91.67)

7 (3.29)
206 (96.71)
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Factor

Use of a translator
Yes
No
Liver disease
Yes
No

Treatment Regimen
9H SAT
n=204 (%)

Treatment
Regimen
3HP DOT
n=213 (%)

p-value

0.5055
12 (5.88)
192 (94.12)

9 (4.23)
204 (95.77)

49 (24.02)
155 (75.98)

37 (17.37)
176 (82.63)

0.0935

Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.
TST: tuberculin skin test. 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. TST:
tuberculin skin test. A cluster represents a group setting; clustered participants represent the first person in a
cluster. This first person underwent randomization and is representative of all participants in the cluster.
a
Median Two-Sample Test using the proc npar1way SAS procedure.
b
Fisher’s exact test
c
Includes North American Indian and other participants in the United States and Canada.
d
History of residing within a correctional institution for ≥ 1 month before enrollment.
e
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse: score of ≥2 on the CAGE questionnaire.
f
Mantel-Haenszel Chi-Square
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Table S3. Factors Associated with Non-completion of LTBI Treatment Among the
First Homeless Participant Enrolled in a Cluster – Univariate Analysis (N=417)
Factor
3HP-DOT (n=204) Ref.
9H-SAT (n=213)
<38 (n=71)
≥38 (n=346) Ref.
Female (n=62) Ref.
Male (n=355)
White (n=155) Ref.
African descendent (n=242)
Asian (n=10)
Othera (n=10)

NCT
(%)
20.19
38.73
31.43
28.82
23.81
30.23
32.47
26.34
30
50

Ethnicity

Non-Hispanic (n=371) Ref.
Hispanic (n=46)

27.42
44.44

0.89
2.08
Ref.
2.12

Siteb

Other sites (n=401)
Site 70 (n=16)

29.18
31.25

0.91
Ref.

0.31-2.67
Ref.

0.86
Ref.

HIV Status

Negative (n=258) Ref.
Positive (n=36)
Unknown (n=123)
Non-U.S (n=54)
U.S. (n=363) Ref.
Underweight (n=7)
Normal (n=122) Ref.
Overweight (168)
Obesity (n=120)
≤8th grade (n=37)
8th grade through some
college (n=354)
≥college degree (n=26) Ref.
Yes (n=159)
No (n=258) Ref.
Yes (n=270) Ref.
No (n=147)
No (n=88) Ref.
Use (n=188)
Abuse (n=141)
No (n=320) Ref.
Yes (n=97)

31.40
33.33
23.58
43.40
27.20
42.86
33.33
30.77
22.03
35.14
28.73

Ref.
1.09
0.67
2.05
Ref.
1.50
Ref.
0.89
0.57
1.39

Ref.
0.52-2.29
0.41-1.10
1.14-3.70
Ref.
0.32-7.02
Ref.
0.54-1.46
0.32-1.00
0.46-4.20

Ref.
0.81
0.12
0.02
Ref.
0.61
Ref.
0.64
0.05
0.56

1.04
Ref.
Ref.
1.64
Ref.
1.15
Ref.
0.74
0.94
Ref.
0.85

0.40-2.56
Ref.
Ref.
1.07-2.51
Ref.
0.74-1.77
Ref.
0.42-1.27
0.53-1.66
Ref.
0.51-1.42

0.94
Ref.
Ref.
0.02
Ref.
0.54
Ref.
0.27
0.83
Ref.
0.54

Treatment
Regimen
Age
Sex
Race

Birthplace
Body Mass
Index

Education

Incarceration

c

Unemployed
Alcohol
Consumptiond
Intravenous
drug user ever
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28
35.63
25.29
28.25
31.08
26.20
31.21
32.58
30
26.80

Odds
Ratio
2.50
Ref.
1.13
Ref.
Ref.
1.39
Ref.
0.74

Confidence
Interval
1.61-3.87
Ref.
0.65-1.97
Ref.
Ref.
0.74-2.58
Ref.
0.48-1.16

P-value

0.22-3.59
0.58-7.51
Ref.
1.13-3.98

0.87
0.26
Ref.
0.02

Ref.
<0.001
0.66
Ref.
Ref.
0.30
Ref
0.19

Factor
Smoking at
Enrollment
Use of
Methadone
Concomitant
medications
LTBI for
contact TB
LTBI for TST
converter
LTBI fibrosis

No (n=112) Ref.
Yes (n=305)
No (n=393) Ref.
Yes (n=24)
No (n=181) Ref.
Yes (n=236)
No (n=155) Ref.
Yes (n=262)
No (n=231) Ref.
Yes (n=186)
No (n=416) Ref.
Yes (n=1)

NCT
(%)
28.32
29.61
29.26
29.17
33.15
26.27
23.08
32.95
32.03
25.81
29.33
0

LTBI for HIV
infection
Missed clinic
visite

No (n=384) Ref.
Yes (n=33)
No (n=377) Ref.
Yes (n=40)

29.43
27.27
25.33
64.29

Odds
Ratio
Ref.
1.07
Ref.
1.00
Ref.
0.72
Ref.
1.64
Ref.
0.74
Ref.
<0.001
Ref.
0.90
Ref.
5.31

Confidence
Interval
Ref.
0.66-1.72
Ref.
0.40-2.47
Ref.
0.47-1.10
Ref.
1.04-2.58
Ref.
0.48-1.13
Ref.
<0.001>999.999
Ref.
0.41-2.00
Ref.
2.71-10.40

P-value
Ref.
0.80
Ref.
0.99
Ref.
0.17
Ref.
0.03
Ref.
0.17
Ref.
0.99
Ref.
0.79
Ref.
<0.001

Abbreviations: NCT: non-completion of treatment; 3HP-DOT, 3 months of directly observed, onceweekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9
months of daily self-administered isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency
virus. BMI: body mass index. TST: tuberculin skin test. A cluster represents a group setting; clustered
participants represent the first person in a cluster. This first person underwent randomization and is
representative of all participants in the cluster.
a
Includes North American Indian and other participants in the United States and Canada.
b
The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.
c
History of residing within a correctional institution for ≥ 1 month before enrollment.
d
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages.
Abuse:
score of ≥2 on the CAGE questionnaire.
e
Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly
clinic visits for the 9H regimen, followed by a DOT or a monthly visit, respectively.
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Table S4. Factors Associated with LTBI Non-completion of Treatment Among the
First Participant Enrolled in a Cluster - Multivariate Analysis (N=417)
Factor
Treatment Regimen
3HP
9H
Birthplace in the U.S.
Yes
No
Incarceration a
Yes
No
Missed clinic visit
Yes
No

Odds Ratio (95% CI)

p-value

Ref.
2.23 (1.41, 3.53)

0.0006

Ref.
2.81 (1.48, 5.35)

Ref.
0.0016

2.06 (1.28, 3.32)
Ref.

0.0029

5.16 (2.55, 10.46)
Ref.

<0.0001

Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900
mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid. A
cluster represents a group setting; clustered participants represent the first person in a cluster. This first
person underwent randomization and is representative of all participants in the cluster.
a
History of residing within a correctional institution for ≥ 1 month before enrollment.
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